Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 3
2019 18
2020 20
2021 22
2022 7
2023 10
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Results by year

Filters applied: . Clear all
Page 1
Morphologic and Molecular Heterogeneity of High-grade Serous Carcinoma Precursor Lesions.
Chien YW, Wang Y, Huang P, Lawson BC, Kolin DL, Chui MH, Vang R, Numan TA, Soong TR, Wang BG, Smith SA, Chen CL, Stone R, Douville C, Wang TL, Shih IM. Chien YW, et al. Am J Surg Pathol. 2024 Apr 1;48(4):475-486. doi: 10.1097/PAS.0000000000002187. Epub 2024 Feb 1. Am J Surg Pathol. 2024. PMID: 38298022 Free PMC article.
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer.
Kinose Y, Xu H, Kim H, Kumar S, Shan X, George E, Wang X, Medvedev S, Ferman B, Gitto SB, Whicker M, D'Andrea K, Wubbenhorst B, Hallberg D, O'Connor M, Schwartz LE, Hwang WT, Nathanson KL, Mills GB, Velculescu VE, Wang TL, Brown EJ, Drapkin R, Simpkins F. Kinose Y, et al. Res Sq [Preprint]. 2023 Sep 27:rs.3.rs-3314138. doi: 10.21203/rs.3.rs-3314138/v1. Res Sq. 2023. PMID: 37841875 Free PMC article. Preprint.
Ultrasensitive Detection of Circulating LINE-1 ORF1p as a Specific Multicancer Biomarker.
Taylor MS, Wu C, Fridy PC, Zhang SJ, Senussi Y, Wolters JC, Cajuso T, Cheng WC, Heaps JD, Miller BD, Mori K, Cohen L, Jiang H, Molloy KR, Chait BT, Goggins MG, Bhan I, Franses JW, Yang X, Taplin ME, Wang X, Christiani DC, Johnson BE, Meyerson M, Uppaluri R, Egloff AM, Denault EN, Spring LM, Wang TL, Shih IM, Fairman JE, Jung E, Arora KS, Yilmaz OH, Cohen S, Sharova T, Chi G, Norden BL, Song Y, Nieman LT, Pappas L, Parikh AR, Strickland MR, Corcoran RB, Mustelin T, Eng G, Yilmaz ÖH, Matulonis UA, Chan AT, Skates SJ, Rueda BR, Drapkin R, Klempner SJ, Deshpande V, Ting DT, Rout MP, LaCava J, Walt DR, Burns KH. Taylor MS, et al. Cancer Discov. 2023 Dec 12;13(12):2532-2547. doi: 10.1158/2159-8290.CD-23-0313. Cancer Discov. 2023. PMID: 37698949 Free PMC article.
Telehealth utilization in gynecologic oncology clinical trials.
Andriani L, Oh J, McMinn E, Gleason E, Koelper NC, Chittams J, Simpkins F, Ko EM. Andriani L, et al. Gynecol Oncol. 2023 Oct;177:103-108. doi: 10.1016/j.ygyno.2023.08.011. Epub 2023 Aug 31. Gynecol Oncol. 2023. PMID: 37659265 Free article.
Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
Yu ZC, Li T, Tully E, Huang P, Chen CN, Oberdoerffer P, Gaillard S, Shih IM, Wang TL. Yu ZC, et al. Cancer Res. 2023 Aug 15;83(16):2750-2762. doi: 10.1158/0008-5472.CAN-22-3646. Cancer Res. 2023. PMID: 37306706 Free PMC article.
74 results